Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) Operating Expenses: 2021-2024

Historic Operating Expenses for Abivax (ABVX) over the last 4 years, with Dec 2024 value amounting to $198.2 million.

  • Abivax's Operating Expenses fell 22.14% to -$53.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$148.7 million, marking a year-over-year decrease of 58.29%. This contributed to the annual value of $198.2 million for FY2024, which is 39.52% up from last year.
  • According to the latest figures from FY2024, Abivax's Operating Expenses is $198.2 million, which was up 39.52% from $142.0 million recorded in FY2023.
  • Abivax's 5-year Operating Expenses high stood at $198.2 million for FY2024, and its period low was $63.1 million during FY2021.
  • For the 3-year period, Abivax's Operating Expenses averaged around $137.8 million, with its median value being $142.0 million (2023).
  • Data for Abivax's Operating Expenses shows a peak YoY skyrocketed of 94.11% (in 2023) over the last 5 years.
  • Abivax's Operating Expenses (Yearly) stood at $63.1 million in 2021, then rose by 15.86% to $73.2 million in 2022, then soared by 94.11% to $142.0 million in 2023, then spiked by 39.52% to $198.2 million in 2024.